View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsGlobal Bioenergies 将来の成長Future 基準チェック /06現在、 Global Bioenergiesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長43.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Breakeven Date Change • Mar 31No longer forecast to breakevenThe analyst covering Global Bioenergies no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €4.70m in 2025. New forecast suggests the company will make a loss of €1.30m in 2025.Breakeven Date Change • Feb 21Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests losses will reduce by 31% per year to 2024. The company is expected to make a profit of €4.70m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.Breakeven Date Change • Feb 14Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests the company will make a profit of €4.70m in 2025. Average annual earnings growth of 39% is required to achieve expected profit on schedule.Breakeven Date Change • Mar 06Forecast to breakeven in 2024The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests losses will reduce by 20% per year to 2023. The company is expected to make a profit of €700.0k in 2024. Average annual earnings growth of 56% is required to achieve expected profit on schedule.Breakeven Date Change • Feb 01Forecast to breakeven in 2024The 2 analysts covering Global Bioenergies expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €700.0k in 2024. Average annual earnings growth of 48% is required to achieve expected profit on schedule.Breakeven Date Change • May 19No longer forecast to breakevenThe 2 analysts covering Global Bioenergies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €4.20m in 2023. New consensus forecast suggests the company will make a loss of €7.65m in 2023.すべての更新を表示Recent updatesBoard Change • Nov 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Marie-Odile Lavenant was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Oct 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Marie-Odile Lavenant was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Marie-Odile Lavenant was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Apr 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Pierre Monsan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Mar 22Global Bioenergies SA, Annual General Meeting, May 15, 2025Global Bioenergies SA, Annual General Meeting, May 15, 2025. Location: 5 rue henri desbrueres, evry courcouronnes FranceBoard Change • Jan 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Pierre Monsan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Nov 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Pierre Monsan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.New Risk • Oct 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.84m (US$9.58m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-€146k). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Revenue is less than US$1m (€535k revenue, or US$580k). Market cap is less than US$10m (€8.84m market cap, or US$9.58m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.5m net loss in 2 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding).New Risk • Oct 10New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€146k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-€146k). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Revenue is less than US$1m (€535k revenue, or US$585k). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.5m net loss in 2 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (€24.0m market cap, or US$26.2m).Board Change • Aug 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Jun 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.New Risk • May 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 4.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€9.5m net loss in 2 years). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (€33.2m market cap, or US$36.1m).お知らせ • May 12Global Bioenergies SA, Annual General Meeting, Jun 27, 2024Global Bioenergies SA, Annual General Meeting, Jun 27, 2024. Location: 5 rue henri desbrueres, evry courcouronnes FranceNew Risk • Apr 12New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 6.0% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€9.5m net loss in 2 years). Market cap is less than US$100m (€36.9m market cap, or US$39.3m).Board Change • Apr 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Mar 08Full year 2023 earnings releasedFull year 2023 results: Revenue: €8.91m (up €8.33m from FY 2022). Net loss: €8.66m (loss narrowed 28% from FY 2022). Revenue is expected to decline by 53% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.6%.Board Change • Dec 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Oct 19Global Bioenergies Announces the Appointment of Martin Stephan as Chief Business OfficerGlobal Bioenergies announced Martin Stephan joins the company as chief business officer. Martin Stephan has spent his entire career in the chemical industry, in France, Germany, Italy and Switzerland. As Deputy Chief Executive Officer of CARBIOS from 2017 to 2022, he notably contributed to the strong growth of this major listed player in the green chemistry market. He previously held strategic positions as Head of International Sales in global groups, particularly in The Chemours Company and Du Pont de Nemours, the world leader in innovative specialty products for industry. Martin Stephan is a graduate of HEC.Board Change • Oct 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Apr 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Breakeven Date Change • Mar 31No longer forecast to breakevenThe analyst covering Global Bioenergies no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €4.70m in 2025. New forecast suggests the company will make a loss of €1.30m in 2025.Breakeven Date Change • Feb 21Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests losses will reduce by 31% per year to 2024. The company is expected to make a profit of €4.70m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.Reported Earnings • Feb 17Full year 2022 earnings releasedFull year 2022 results: Revenue: €1.72m (up 106% from FY 2021). Net loss: €12.0m (loss widened 1.8% from FY 2021). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Chemicals industry in Germany.Breakeven Date Change • Feb 14Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests the company will make a profit of €4.70m in 2025. Average annual earnings growth of 39% is required to achieve expected profit on schedule.お知らせ • Sep 23Global Bioenergies SA Completes REWOFUEL ProjectGlobal Bioenergies SA announced the end of the REWOFUEL project, which ran from 1 June 2018 to 30 June 2022. This project brought together several European industries such as Repsol, Sekab and Fibenol, with the objective of demonstrating the conversion of wood residues into sustainable high-performance components for road and aviation fuels,and thus participate to the decarbonization efforts of ground and air transportation. The project was coordinated by Global Bioenergies and received €13.8 million in funding from the European Horizon 2020 research and innovation programme. For this project, sugars from wood were supplied by Sekab and Fibenol. These sugars were then processed into high performance sustainable biofuels. As a result, batches of bio-isooctane, bio-ETBE and sustainable aviation fuel have been produced by Global Bioenergies and then tested by Repsol, Spain’s leading oil company. Batches of sustainable aviation fuel were produced and transferred to SkyNRG, leader in the sustainable aviation fuel industry. Significant work has been coordinated by SkyNRG for the certification of these isobutene derivatives as a sustainable aviation fuel. Meanwhile, by-products from the ligneous part of wood chips have been incorporated by Peab into successfully implemented bitumen products. Producing bitumen with a better environmental footprint will help to optimise overall road transport performance. The proteins resulting from fermentation are intended to be used in animal feed. The experiments conducted by Metex NoovistaGo in this respect have produced positive results. Finally, the Energie Institut JKU has carried out life cycle analyses of the various segments of this value chain and has quantified the reduction in CO2 emissions according to different configurations, which can lead to savings of up to 85% compared to the benchmark fossil solution. Meanwhile, engineering efforts have been conducted by Neste, Technip-FMC, and IPSB, a French engineering company specialized in agribusinesses.Breakeven Date Change • Mar 06Forecast to breakeven in 2024The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests losses will reduce by 20% per year to 2023. The company is expected to make a profit of €700.0k in 2024. Average annual earnings growth of 56% is required to achieve expected profit on schedule.お知らせ • Feb 10Global Bioenergies Announces New Molecule for the Greening of C5 ChemistryGlobal Bioenergies has developed a process for converting plant resources into isobutene, one of the main building blocks of chemistry, whose derivatives are used in cosmetics, fine chemicals, commodities and fuels. A production unit is currently under construction in Pomacle to serve high value-added markets. One of the intermediates in the isobutene synthesis pathway is of industrial interest: this 5-carbon intermediate, prenic acid, is also known as “methyl-crotonic acid”, “dimethyl-acrylic acid” and “senecic acid” (CAS 541-47-9). Its two chemical functions (acid and vinyl) allow it to be used in a multitude of compounds that are currently derived from petroleum and used most notably in flavours, perfumes and food additives. A non-exhaustive overview of the prenic acid product tree is available on the Technology page of the Global Bioenergies website: it illustrates the range of products and domains accessible from this molecule.Breakeven Date Change • Feb 01Forecast to breakeven in 2024The 2 analysts covering Global Bioenergies expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €700.0k in 2024. Average annual earnings growth of 48% is required to achieve expected profit on schedule.Reported Earnings • Oct 03First half 2021 earnings released: €0.69 loss per share (vs €0.80 loss in 1H 2020)First half 2021 results: Net loss: €7.62m (loss widened 9.9% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.お知らせ • Sep 15Global Bioenergies Launches Lip Make-Up Range for Its Last Cosmetics BrandGlobal Bioenergies announced the launch of a lip make-up range for its LAST brand, in addition to the existing eye make-up offer. Like the 18 mascara, eyebrow mascara and liquid eyeshadow products on the market since June, the 14 liquid lipsticks are a combination of high performance and high naturalness. This combination is only possible Global Bioenergies innovative product: naturally sourced isododecane.お知らせ • Jul 02Global Bioenergies Releases Second Commercial Batch of Naturally Sourced IsododecaneGlobal Bioenergies SA has finished producing and released its second batch of naturally sourced isododecane. Besides fuelling the Company’s own brand, LAST, this batch will also be used to distribute product samples to the many cosmetic industry players who have requested it. Six months after releasing its first batch of naturally sourced isododecane, Global Bioenergies has finished producing and released a second batch of the innovative ingredient to be marketed from 2022 under the name of Isonaturane 12. The second batch of naturally sourced isododecane is also used to serve the numerous cosmetic industry players who have requested sampling.お知らせ • Jun 15Global Bioenergies Launches of LAST brandGlobal Bioenergies launches its LAST brand, the first range of longwear make-up with over 90% natural ingredients: the range’s 18 mascara, eyebrow mascara and eye shadow products can now be obtained. Instrumental tests and clinical studies demonstrate performance on a par with the best conventional products on the market: this is the first time a brand with over 90% natural ingredients has delivered such a performance. Independent laboratories conducted numerous instrumental tests and clinical tolerance and use studies on the products. The performance of the range was compared to leading products on the market in terms of hold, water resistance, level of transfer, sensory qualities and pleasure of application. The results demonstrate 24-hour hold, waterproofness and low-transfer property for each of the product categories. Tests conducted over a long period (21 days) under dermatological and ophthalmological supervision validated tolerance to use. The products’ sensory qualities were also highly appreciated: for example, after blind testing, 85% of women said they would like to continue using LAST eye shadow and would recommend it to their friends, considering that, independently of naturalness, the product is equivalent to or better than their usual eye shadow.Breakeven Date Change • May 19No longer forecast to breakevenThe 2 analysts covering Global Bioenergies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €4.20m in 2023. New consensus forecast suggests the company will make a loss of €7.65m in 2023.お知らせ • May 05Global Bioenergies Announces the Upcoming Launch of “LAST®” Longwear CosmeticsGlobal Bioenergies announced the upcoming launch of its “LAST®” longwear cosmetics brand in June 2021. This groundbreaking performance is based on the renewable isododecane produced by the Company as the main ingredient of its formulations. Products have been designed with over 90% natural ingredients and packaging to minimise their environmental footprint. Prototypes were refined and went into industrial production at one of Europe’s leading make-up manufacturers. Packaging made from mineral (glass or metal), biosourced or recycled materials was specified, designed and prototyped. The LAST® brand currently has three categories of product: mascaras, eyebrow mascaras and eye shadows, all lasting at least 24 hours. Allowing for the different colours, the full range has 18 products, now in production in a French plant.Reported Earnings • Apr 26Full year 2020 earnings released: €1.10 loss per share (vs €1.65 loss in FY 2019)Full year 2020 results: Net loss: €11.1m (loss narrowed 23% from FY 2019). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 20Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €3.28m (up €3.16m from FY 2019). Net loss: €11.1m (loss narrowed 13% from FY 2019).Is New 90 Day High Low • Jan 15New 90-day high: €9.26The company is up 194% from its price of €3.15 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period.Is New 90 Day High Low • Nov 25New 90-day high: €3.90The company is up 11% from its price of €3.51 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 8.0% over the same period.Reported Earnings • Sep 21First half earnings releasedOver the last 12 months the company has reported total losses of €12.1m, with losses narrowing by 2.5% from the prior year. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Global Bioenergies は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BST:1DK - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20240-6-8-8N/A9/30/20243-7N/AN/AN/A6/30/20240-7-5-4N/A3/31/20242-8-6-6N/A12/31/20233-9-8-8N/A9/30/20232-9N/AN/AN/A6/30/20234-10-9-8N/A3/31/20232-11-11-9N/A12/31/20221-12-12-10N/A9/30/20221-11N/AN/AN/A6/30/20221-10-14-11N/A3/31/20221-11-14-12N/A12/31/20211-12-15-12N/A9/30/20210-12N/AN/AN/A6/30/20210-12-30-28N/A3/31/20210-11-21-19N/A12/31/20200-11-11-11N/A9/30/20200-13-4-3N/A6/30/20200-1245N/A3/31/20200-12-3-3N/A12/31/20190-14-11-10N/A9/30/20191-13N/AN/AN/A6/30/20191-12-16-16N/A3/31/20191-13-12-12N/A12/31/20181-14-8-7N/A9/30/20181-16N/AN/AN/A6/30/20180-17N/A-5N/A3/31/20180-16N/A-7N/A12/31/20170-14N/A-9N/A9/30/20170-11N/AN/AN/A6/30/20171-10N/A-6N/A3/31/20171-10N/A-8N/A12/31/20161-11N/A-9N/A9/30/20160-11N/AN/AN/A6/30/20161-11N/A-9N/A3/31/20161-11N/A-10N/A12/31/20151-10N/A-9N/A9/30/20151-9N/AN/AN/A6/30/20151-8N/A-8N/A3/31/20152-7N/A-8N/A12/31/20142-6N/A-7N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1DKの予測収益成長が 貯蓄率 ( 1.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 1DKの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 1DKの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 1DKの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 1DKの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1DKの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/12/05 16:50終値2025/12/01 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Global Bioenergies SA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Markus MayerBaader Helvea Equity ResearchMark CartlichEdison Investment ResearchAlexandre LetzGilbert Dupont3 その他のアナリストを表示
Breakeven Date Change • Mar 31No longer forecast to breakevenThe analyst covering Global Bioenergies no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €4.70m in 2025. New forecast suggests the company will make a loss of €1.30m in 2025.
Breakeven Date Change • Feb 21Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests losses will reduce by 31% per year to 2024. The company is expected to make a profit of €4.70m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.
Breakeven Date Change • Feb 14Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests the company will make a profit of €4.70m in 2025. Average annual earnings growth of 39% is required to achieve expected profit on schedule.
Breakeven Date Change • Mar 06Forecast to breakeven in 2024The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests losses will reduce by 20% per year to 2023. The company is expected to make a profit of €700.0k in 2024. Average annual earnings growth of 56% is required to achieve expected profit on schedule.
Breakeven Date Change • Feb 01Forecast to breakeven in 2024The 2 analysts covering Global Bioenergies expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €700.0k in 2024. Average annual earnings growth of 48% is required to achieve expected profit on schedule.
Breakeven Date Change • May 19No longer forecast to breakevenThe 2 analysts covering Global Bioenergies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €4.20m in 2023. New consensus forecast suggests the company will make a loss of €7.65m in 2023.
Board Change • Nov 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Marie-Odile Lavenant was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Oct 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Marie-Odile Lavenant was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Marie-Odile Lavenant was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Apr 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Pierre Monsan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Mar 22Global Bioenergies SA, Annual General Meeting, May 15, 2025Global Bioenergies SA, Annual General Meeting, May 15, 2025. Location: 5 rue henri desbrueres, evry courcouronnes France
Board Change • Jan 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Pierre Monsan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Nov 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Pierre Monsan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
New Risk • Oct 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.84m (US$9.58m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-€146k). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Revenue is less than US$1m (€535k revenue, or US$580k). Market cap is less than US$10m (€8.84m market cap, or US$9.58m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.5m net loss in 2 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding).
New Risk • Oct 10New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€146k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-€146k). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Revenue is less than US$1m (€535k revenue, or US$585k). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.5m net loss in 2 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (€24.0m market cap, or US$26.2m).
Board Change • Aug 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Jun 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
New Risk • May 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 4.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€9.5m net loss in 2 years). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (€33.2m market cap, or US$36.1m).
お知らせ • May 12Global Bioenergies SA, Annual General Meeting, Jun 27, 2024Global Bioenergies SA, Annual General Meeting, Jun 27, 2024. Location: 5 rue henri desbrueres, evry courcouronnes France
New Risk • Apr 12New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 6.0% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€9.5m net loss in 2 years). Market cap is less than US$100m (€36.9m market cap, or US$39.3m).
Board Change • Apr 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Mar 08Full year 2023 earnings releasedFull year 2023 results: Revenue: €8.91m (up €8.33m from FY 2022). Net loss: €8.66m (loss narrowed 28% from FY 2022). Revenue is expected to decline by 53% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.6%.
Board Change • Dec 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Oct 19Global Bioenergies Announces the Appointment of Martin Stephan as Chief Business OfficerGlobal Bioenergies announced Martin Stephan joins the company as chief business officer. Martin Stephan has spent his entire career in the chemical industry, in France, Germany, Italy and Switzerland. As Deputy Chief Executive Officer of CARBIOS from 2017 to 2022, he notably contributed to the strong growth of this major listed player in the green chemistry market. He previously held strategic positions as Head of International Sales in global groups, particularly in The Chemours Company and Du Pont de Nemours, the world leader in innovative specialty products for industry. Martin Stephan is a graduate of HEC.
Board Change • Oct 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Apr 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Breakeven Date Change • Mar 31No longer forecast to breakevenThe analyst covering Global Bioenergies no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €4.70m in 2025. New forecast suggests the company will make a loss of €1.30m in 2025.
Breakeven Date Change • Feb 21Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests losses will reduce by 31% per year to 2024. The company is expected to make a profit of €4.70m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.
Reported Earnings • Feb 17Full year 2022 earnings releasedFull year 2022 results: Revenue: €1.72m (up 106% from FY 2021). Net loss: €12.0m (loss widened 1.8% from FY 2021). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Chemicals industry in Germany.
Breakeven Date Change • Feb 14Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests the company will make a profit of €4.70m in 2025. Average annual earnings growth of 39% is required to achieve expected profit on schedule.
お知らせ • Sep 23Global Bioenergies SA Completes REWOFUEL ProjectGlobal Bioenergies SA announced the end of the REWOFUEL project, which ran from 1 June 2018 to 30 June 2022. This project brought together several European industries such as Repsol, Sekab and Fibenol, with the objective of demonstrating the conversion of wood residues into sustainable high-performance components for road and aviation fuels,and thus participate to the decarbonization efforts of ground and air transportation. The project was coordinated by Global Bioenergies and received €13.8 million in funding from the European Horizon 2020 research and innovation programme. For this project, sugars from wood were supplied by Sekab and Fibenol. These sugars were then processed into high performance sustainable biofuels. As a result, batches of bio-isooctane, bio-ETBE and sustainable aviation fuel have been produced by Global Bioenergies and then tested by Repsol, Spain’s leading oil company. Batches of sustainable aviation fuel were produced and transferred to SkyNRG, leader in the sustainable aviation fuel industry. Significant work has been coordinated by SkyNRG for the certification of these isobutene derivatives as a sustainable aviation fuel. Meanwhile, by-products from the ligneous part of wood chips have been incorporated by Peab into successfully implemented bitumen products. Producing bitumen with a better environmental footprint will help to optimise overall road transport performance. The proteins resulting from fermentation are intended to be used in animal feed. The experiments conducted by Metex NoovistaGo in this respect have produced positive results. Finally, the Energie Institut JKU has carried out life cycle analyses of the various segments of this value chain and has quantified the reduction in CO2 emissions according to different configurations, which can lead to savings of up to 85% compared to the benchmark fossil solution. Meanwhile, engineering efforts have been conducted by Neste, Technip-FMC, and IPSB, a French engineering company specialized in agribusinesses.
Breakeven Date Change • Mar 06Forecast to breakeven in 2024The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests losses will reduce by 20% per year to 2023. The company is expected to make a profit of €700.0k in 2024. Average annual earnings growth of 56% is required to achieve expected profit on schedule.
お知らせ • Feb 10Global Bioenergies Announces New Molecule for the Greening of C5 ChemistryGlobal Bioenergies has developed a process for converting plant resources into isobutene, one of the main building blocks of chemistry, whose derivatives are used in cosmetics, fine chemicals, commodities and fuels. A production unit is currently under construction in Pomacle to serve high value-added markets. One of the intermediates in the isobutene synthesis pathway is of industrial interest: this 5-carbon intermediate, prenic acid, is also known as “methyl-crotonic acid”, “dimethyl-acrylic acid” and “senecic acid” (CAS 541-47-9). Its two chemical functions (acid and vinyl) allow it to be used in a multitude of compounds that are currently derived from petroleum and used most notably in flavours, perfumes and food additives. A non-exhaustive overview of the prenic acid product tree is available on the Technology page of the Global Bioenergies website: it illustrates the range of products and domains accessible from this molecule.
Breakeven Date Change • Feb 01Forecast to breakeven in 2024The 2 analysts covering Global Bioenergies expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €700.0k in 2024. Average annual earnings growth of 48% is required to achieve expected profit on schedule.
Reported Earnings • Oct 03First half 2021 earnings released: €0.69 loss per share (vs €0.80 loss in 1H 2020)First half 2021 results: Net loss: €7.62m (loss widened 9.9% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
お知らせ • Sep 15Global Bioenergies Launches Lip Make-Up Range for Its Last Cosmetics BrandGlobal Bioenergies announced the launch of a lip make-up range for its LAST brand, in addition to the existing eye make-up offer. Like the 18 mascara, eyebrow mascara and liquid eyeshadow products on the market since June, the 14 liquid lipsticks are a combination of high performance and high naturalness. This combination is only possible Global Bioenergies innovative product: naturally sourced isododecane.
お知らせ • Jul 02Global Bioenergies Releases Second Commercial Batch of Naturally Sourced IsododecaneGlobal Bioenergies SA has finished producing and released its second batch of naturally sourced isododecane. Besides fuelling the Company’s own brand, LAST, this batch will also be used to distribute product samples to the many cosmetic industry players who have requested it. Six months after releasing its first batch of naturally sourced isododecane, Global Bioenergies has finished producing and released a second batch of the innovative ingredient to be marketed from 2022 under the name of Isonaturane 12. The second batch of naturally sourced isododecane is also used to serve the numerous cosmetic industry players who have requested sampling.
お知らせ • Jun 15Global Bioenergies Launches of LAST brandGlobal Bioenergies launches its LAST brand, the first range of longwear make-up with over 90% natural ingredients: the range’s 18 mascara, eyebrow mascara and eye shadow products can now be obtained. Instrumental tests and clinical studies demonstrate performance on a par with the best conventional products on the market: this is the first time a brand with over 90% natural ingredients has delivered such a performance. Independent laboratories conducted numerous instrumental tests and clinical tolerance and use studies on the products. The performance of the range was compared to leading products on the market in terms of hold, water resistance, level of transfer, sensory qualities and pleasure of application. The results demonstrate 24-hour hold, waterproofness and low-transfer property for each of the product categories. Tests conducted over a long period (21 days) under dermatological and ophthalmological supervision validated tolerance to use. The products’ sensory qualities were also highly appreciated: for example, after blind testing, 85% of women said they would like to continue using LAST eye shadow and would recommend it to their friends, considering that, independently of naturalness, the product is equivalent to or better than their usual eye shadow.
Breakeven Date Change • May 19No longer forecast to breakevenThe 2 analysts covering Global Bioenergies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €4.20m in 2023. New consensus forecast suggests the company will make a loss of €7.65m in 2023.
お知らせ • May 05Global Bioenergies Announces the Upcoming Launch of “LAST®” Longwear CosmeticsGlobal Bioenergies announced the upcoming launch of its “LAST®” longwear cosmetics brand in June 2021. This groundbreaking performance is based on the renewable isododecane produced by the Company as the main ingredient of its formulations. Products have been designed with over 90% natural ingredients and packaging to minimise their environmental footprint. Prototypes were refined and went into industrial production at one of Europe’s leading make-up manufacturers. Packaging made from mineral (glass or metal), biosourced or recycled materials was specified, designed and prototyped. The LAST® brand currently has three categories of product: mascaras, eyebrow mascaras and eye shadows, all lasting at least 24 hours. Allowing for the different colours, the full range has 18 products, now in production in a French plant.
Reported Earnings • Apr 26Full year 2020 earnings released: €1.10 loss per share (vs €1.65 loss in FY 2019)Full year 2020 results: Net loss: €11.1m (loss narrowed 23% from FY 2019). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 20Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €3.28m (up €3.16m from FY 2019). Net loss: €11.1m (loss narrowed 13% from FY 2019).
Is New 90 Day High Low • Jan 15New 90-day high: €9.26The company is up 194% from its price of €3.15 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period.
Is New 90 Day High Low • Nov 25New 90-day high: €3.90The company is up 11% from its price of €3.51 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 8.0% over the same period.
Reported Earnings • Sep 21First half earnings releasedOver the last 12 months the company has reported total losses of €12.1m, with losses narrowing by 2.5% from the prior year.